Cargando…

Clinical outcomes of patients with metachronous second primary lung adenocarcinomas

BACKGROUND: The incidence of adenocarcinomas as multiple primary lung cancers (MPLCs) is increasing. How to determine the treatment strategies of MPLCs, especially second primary lung adenocarcinomas (SPLACs), and the prognostic factors associated with it are unclear. METHODS: The clinical records o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Heng, Yang, Haitang, Han, Ke, Xu, Jianlin, Yao, Feng, Zhao, Yang, Fan, Liwen, Gu, Haiyong, Shen, Zhenya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237587/
https://www.ncbi.nlm.nih.gov/pubmed/28138252
http://dx.doi.org/10.2147/OTT.S122908
_version_ 1782495555675488256
author Zhao, Heng
Yang, Haitang
Han, Ke
Xu, Jianlin
Yao, Feng
Zhao, Yang
Fan, Liwen
Gu, Haiyong
Shen, Zhenya
author_facet Zhao, Heng
Yang, Haitang
Han, Ke
Xu, Jianlin
Yao, Feng
Zhao, Yang
Fan, Liwen
Gu, Haiyong
Shen, Zhenya
author_sort Zhao, Heng
collection PubMed
description BACKGROUND: The incidence of adenocarcinomas as multiple primary lung cancers (MPLCs) is increasing. How to determine the treatment strategies of MPLCs, especially second primary lung adenocarcinomas (SPLACs), and the prognostic factors associated with it are unclear. METHODS: The clinical records of patients undergoing surgery for second adenocarcinomas based on Martini–Melamed criteria between 2001 and 2014 were retrospectively reviewed. Survival rates were calculated by the Kaplan–Meier method and compared using the log-rank test. Multivariate analysis was conducted using the Cox proportional hazards model. RESULTS: A total of 115 patients with SPLACs were identified based on Martini–Melamed criteria. With respect to the second resections, three subgroups with low- (adenocarcinoma in situ, n=6; minimally invasive adenocarcinoma, n=19), intermediate- (lepidic, n=9; acinar, n=40; papillary, n=23), and high-grades (solid, n=9; micropapillary, n=2; invasive mucinous, n=7) were assigned. The 5-year overall survival (OS) rates from the time of the first and the second resections were 86.5% and 69.5%, respectively. Cox multivariate analysis identified computed tomography (CT) morphology of SPLACs (ground glass opacity predominant versus solid predominant; hazard ratio [HR]=0.42; P=0.036), histologic classification (same/similar vs different; HR=0.06; P<0.001), pathologic stage of the primary (stage I vs II; HR=0.20; P=0.015) and second tumors (stage I vs IIIa; HR=0.21; P=0.002), and histologic grade of SPLACs (low- vs high-grade, HR=0.05, P=0.016; intermediate- vs high-grade, HR=0.37, P=0.027) as significantly favorable prognostic factors for OS. CONCLUSION: In addition to pathologic stage of the initial tumors and histologic classification, pathologic stage and CT morphology of SPLACs were identified as predictors of survival. The histologic grade of SPLACs based on the new adenocarcinoma classification could provide additional prognostic information.
format Online
Article
Text
id pubmed-5237587
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-52375872017-01-30 Clinical outcomes of patients with metachronous second primary lung adenocarcinomas Zhao, Heng Yang, Haitang Han, Ke Xu, Jianlin Yao, Feng Zhao, Yang Fan, Liwen Gu, Haiyong Shen, Zhenya Onco Targets Ther Original Research BACKGROUND: The incidence of adenocarcinomas as multiple primary lung cancers (MPLCs) is increasing. How to determine the treatment strategies of MPLCs, especially second primary lung adenocarcinomas (SPLACs), and the prognostic factors associated with it are unclear. METHODS: The clinical records of patients undergoing surgery for second adenocarcinomas based on Martini–Melamed criteria between 2001 and 2014 were retrospectively reviewed. Survival rates were calculated by the Kaplan–Meier method and compared using the log-rank test. Multivariate analysis was conducted using the Cox proportional hazards model. RESULTS: A total of 115 patients with SPLACs were identified based on Martini–Melamed criteria. With respect to the second resections, three subgroups with low- (adenocarcinoma in situ, n=6; minimally invasive adenocarcinoma, n=19), intermediate- (lepidic, n=9; acinar, n=40; papillary, n=23), and high-grades (solid, n=9; micropapillary, n=2; invasive mucinous, n=7) were assigned. The 5-year overall survival (OS) rates from the time of the first and the second resections were 86.5% and 69.5%, respectively. Cox multivariate analysis identified computed tomography (CT) morphology of SPLACs (ground glass opacity predominant versus solid predominant; hazard ratio [HR]=0.42; P=0.036), histologic classification (same/similar vs different; HR=0.06; P<0.001), pathologic stage of the primary (stage I vs II; HR=0.20; P=0.015) and second tumors (stage I vs IIIa; HR=0.21; P=0.002), and histologic grade of SPLACs (low- vs high-grade, HR=0.05, P=0.016; intermediate- vs high-grade, HR=0.37, P=0.027) as significantly favorable prognostic factors for OS. CONCLUSION: In addition to pathologic stage of the initial tumors and histologic classification, pathologic stage and CT morphology of SPLACs were identified as predictors of survival. The histologic grade of SPLACs based on the new adenocarcinoma classification could provide additional prognostic information. Dove Medical Press 2017-01-10 /pmc/articles/PMC5237587/ /pubmed/28138252 http://dx.doi.org/10.2147/OTT.S122908 Text en © 2017 Zhao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zhao, Heng
Yang, Haitang
Han, Ke
Xu, Jianlin
Yao, Feng
Zhao, Yang
Fan, Liwen
Gu, Haiyong
Shen, Zhenya
Clinical outcomes of patients with metachronous second primary lung adenocarcinomas
title Clinical outcomes of patients with metachronous second primary lung adenocarcinomas
title_full Clinical outcomes of patients with metachronous second primary lung adenocarcinomas
title_fullStr Clinical outcomes of patients with metachronous second primary lung adenocarcinomas
title_full_unstemmed Clinical outcomes of patients with metachronous second primary lung adenocarcinomas
title_short Clinical outcomes of patients with metachronous second primary lung adenocarcinomas
title_sort clinical outcomes of patients with metachronous second primary lung adenocarcinomas
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237587/
https://www.ncbi.nlm.nih.gov/pubmed/28138252
http://dx.doi.org/10.2147/OTT.S122908
work_keys_str_mv AT zhaoheng clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas
AT yanghaitang clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas
AT hanke clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas
AT xujianlin clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas
AT yaofeng clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas
AT zhaoyang clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas
AT fanliwen clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas
AT guhaiyong clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas
AT shenzhenya clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas